# CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

> **NCT02259556** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** CART30

## Key facts

- **NCT ID:** NCT02259556
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-10
- **Primary completion:** 2018-10
- **Final completion:** 2029-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259556, "CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02259556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*